Abstracts tagged "Interleukins"

Abstract Number: 0278 • ACR Convergence 2024
Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Songping Li⁸, Songbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shenyang, China (People's Republic), ⁶Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of Ganna Medical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department of Rheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…
Abstract Number: 2585 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Stefan Siebert¹, Mohamed Sharaf², Carlo Selmi³, Proton Rahman⁴, Mitsumasa Kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Minni Koivunen⁹, Frederic Lavie¹⁰, Ruben Queiro Silva¹¹, Frank Behrens¹², Ennio Lubrano¹³ and Laure Gossec¹⁴, ¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ³Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ⁴Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, ⁹Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, ¹⁰Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹¹Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹²University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ¹³Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ¹⁴Sorbonne Université, Paris, France
Background/Purpose: PsA leads to significant patient-perceived burden of disease. Targeted drugs have demonstrated efficacy in randomised controlled trials including in aspects of patient-reported impact. However,…
Abstract Number: 0303 • ACR Convergence 2024
Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris¹, Jerry Bagel², Yu-Huei Huang³, Andrew E. Pink⁴, Stephen K. Tyring⁵, Georgios Kokolakis⁶, Amy M. DeLozier⁷, Daniel Kakaley⁸, Shu Li⁹, Yaung-Kaung Shen¹⁰, Takayuki Ota⁷ and Robert Bissonnette¹¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Psoriasis Treatment Center of Central NJ, East Windsor, NJ, ³Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), ⁴NHS Foundation Trust Great Maze Pond, London, United Kingdom, ⁵Center for Clinical Studies, Webster, TX, ⁶Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Innovaderm Research, Montreal, QC, Canada
Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
Abstract Number: 2597 • ACR Convergence 2024
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Roopa Madhu², Catherine Manning³, Daniel Montoro⁴, Nataliya Yeremenko⁵, Kevin Wei⁶, ilya Korsunsky¹, Dominique Baeten⁵ and Ellen Gravallese⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Dedham, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: 0562 • ACR Convergence 2024
Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study
Lucia Ondrejčáková¹, Adéla Navrátilová², Monika Gregová³, Kristýna Bubová⁴, Tomáš Grega⁵, Ladislav Šenolt⁶, Karel Pavelka⁷ and Lucie Andrés Cerezo⁸, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, ²1st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁵3Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
Abstract Number: 2616 • ACR Convergence 2024
Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases
Jeffrey Sparks¹, Xiaosong Wang², Pui Lee³, Kailey Brodeur⁴, Miao Lin⁵, Naomi Patel⁵, Yumeko Kawano⁶, Abigail Schiff⁷, Andrew King⁵, Jennifer Hanberg⁶, Shruthi Srivatsan⁵, Emily Kowalski⁶, Colebrook Johnson⁵, Kathleen Vanni⁶, Zachary Williams⁵, Grace Qian², Caleb Bolden⁵, Kevin Mueller⁶, Katarina Bade⁶, Alene Saavedra⁶, Rathnam Venkat⁸ and Zachary Wallace⁹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Boston Children's Hospital, Newton, MA, ⁴Boston Children's Hospital, Cumberland, RI, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Cambridge, MA, ⁸Tufts University School of Medicine, Boston, MA, ⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
Abstract Number: 0585 • ACR Convergence 2024
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Nicole Middaugh², Maya Marchese², Jessica A Walsh³, Natalia Bello⁴, Jeffrey Lisse⁴, Andris Kronbergs⁵, Elsie Grace⁶, Marcus Ngantcha⁴ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
Abstract Number: 2646 • ACR Convergence 2024
Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries
Yosuke Kunishita¹, Urvashi Kaundal², Martin Kerick³, Ryan Routsong⁴, Justin Lack⁴, Ami Shah⁵, Maureen Mayes⁶, Daniel Shriner⁷, Ayo P. Doumatey⁷, Amy Bentley⁷, Robyn Domsic⁸, Thomas Medsger, Jr⁹, Paula Ramos¹⁰, Richard Silver¹¹, Virginia Steen¹², John Varga¹³, Vivien Hsu¹⁴, Lesley Ann Saketkoo¹⁵, Dinesh Khanna¹³, Elena Schiopu¹⁶, Jessica Gordon¹⁷, Lindsey Criswell¹⁸, Heather Gladue¹⁹, Chris Derk²⁰, Elana Bernstein²¹, S. Louis Bridges¹⁷, Victoria Shanmugam²², Lorinda Chung²³, Suzanne Kafaja²⁴, Reem Jan²⁵, Marcin Trojanowski²⁶, Avram Goldberg²⁷, Benjamin Korman²⁸, James W. Thomas²⁹, Elaine Remmers³⁰, Adebowale Adeyemo⁷, Charles Rotimi⁷, Fredrick Wigley³¹, Francesco Boin³², Javier Martin³, Daniel Kastner³³ and Pravitt Gourh³⁴, ¹Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, ³Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ⁴Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁶UTHealth Houston Division of Rheumatology, Houston, TX, ⁷Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ¹²Georgetown University School of Medicine, Washington, DC, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹⁶Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁷Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁸Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²⁰Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²¹Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ²²Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, ²³Stanford University, Woodside, CA, ²⁴Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²⁵Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²⁶Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁷NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁸University of Rochester, Rochester, NY, ²⁹NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³⁰Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³¹Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ³²Cedars-Sinai Medical Center, Los Angeles, CA, ³³National Human Genome Research Institute, Bethesda, MD, ³⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation and fibrosis. Interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor for the Interleukin-1…
Abstract Number: 0605 • ACR Convergence 2024
Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Dennis McGonagle¹, Raja Atreya², Maria Abreu³, James Krueger⁴, Kilian Eyerich⁵, Robert Bissonnette⁶, Carrie Greving⁷, He Li⁸, Tom C. Freeman⁹, Amy Hart⁸, Brice Keyes⁷, Brian Stoveken⁸, John Hartman⁸, Kristin Leppard⁸, Jenna Parrett¹⁰, Joshua Wertheimer⁸, Indra Sarabia⁷, Janise Deming⁷, Kristen Kohler⁷, Christopher Ritchlin¹¹, Iain McInnes¹², Matthieu Allez¹³, Anne Fourie⁷ and Kacey Sachen⁷, ¹National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ²Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Leonard M. Miller School of Medicine, University of Miami, Miami, FL, ⁴The Rockefeller University, Laboratory for Investigative Dermatology, New York, NY, ⁵Karolinska Institute, Department of Medicine – Division of Dermatology and Venereology, Stockholm, Sweden; Medical Center, University of Freiburg, Freiburg, Germany, ⁶Innovaderm Research Inc., Montréal, QC, Canada, ⁷Janssen Research & Development, LLC, Immunology, San Diego, CA, ⁸Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁹Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹³Hôpital Saint-Louis, Université Paris Cité, Paris, France
Background/Purpose: IL-23 is implicated in the pathogenesis of psoriasis (PsO), and myeloid cells that express FcγRI (CD64) have been identified as a primary source of…
Abstract Number: 0606 • ACR Convergence 2024
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Bonit Gill¹, Jack Geiger¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…
Abstract Number: 0880 • ACR Convergence 2024
Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
Charles Besidonne¹, Andrew Benest¹, Kim Chisholm¹, Jonathan Morris², Lucy Donaldson³, Jeanette Woolard⁴ and David Bates¹, ¹University of Nottingham, Nottingham, United Kingdom, ²University of New South Wales, New South Wales, New South Wales, Australia, ³Versus Arthritis UK, Nottingham, United Kingdom, ⁴University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…
Abstract Number: 0920 • ACR Convergence 2024
TGF-β Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation
Paul Panipinto¹ and Salahuddin Ahmed², ¹Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, ²Washington State University, Spokane, WA
Background/Purpose: Monosodium urate (MSU)-induced inflammation is caused by the deposition of MSU crystals in the joints and periarticular tissues under conditions of hyperuricemia. These deposits…
Abstract Number: 1197 • ACR Convergence 2024
Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients
François Rannou¹, Christelle Nguyen¹, Camille Daste¹, Quentin Kirren¹, marie-martine Lefevre-Colau¹, Odile Launay², Lucille Desallais³, Edita Dolimier³, René Azoulai³, Jean-Pierre Salles³ and Jean-François Zagury⁴, ¹AP-HP. Centre-Université Paris Cité, Hôpital Cochin, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Paris, Ile-de-France, France, ²Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France, ³Peptinov, Paris, Ile-de-France, France, ⁴Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire, EA 7528, Chaire de Bioinformatique, Conservatoire National des Arts et Métiers, Paris, Ile-de-France, France
Background/Purpose: Interleukin-6 (IL-6) is a major inflammatory cytokine involved in pain and potentially in osteoarthritis (OA) disease progression. PPV-06 is an IL-6-derived peptide coupled with…
Abstract Number: 1385 • ACR Convergence 2024
A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Yue Zhou, Meng Ji, luo wang, Feihuang Deng, Senping Cheng, Xiaoling Li and Yulian Zhang, Triastek, Inc., Nanjing, China (People's Republic)
Background/Purpose: Patients with inflammatory diseases, such as rheumatoid arthritis (RA), frequently continue to suffer from morning symptoms despite treatment with conventional therapies 1,2. Routine morning…
Abstract Number: 1462 • ACR Convergence 2024
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Philip Mease¹, Ruizhi Zhao², Shannon Ferrante³, Natalie J. Shiff⁴, Pavithra Srinivas⁵, Soumya Chakravarty⁶ and Jessica A Walsh⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs LLC, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ⁷Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…

1
2
3
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].